Companies › Nanjing Leads Biolabs
3 active drug programs in 12 registered trials: 8 Phase 1, 4 Phase 2; Oncology, Immunology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| LBL-024 | – | Phase 2 | Advanced Solid Tumour; Advanced Solid Tumor; Advanced Neuroendocrine Carcinoma; Advanced Melanoma … | Dec 2026 |
| LBL-034 | – | Phase 1 | Relapsed/Refractory Multiple Myeloma | May 2027 |
| LBL-047 | – | Phase 1 | Systemic Lupus Erythematosus | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05170958 | LBL-024 | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2026 |
| NCT06783647 | LBL-024 | Phase 2 | Advanced Solid Tumour | Oncology | Dec 2026 |
| NCT06157827 | LBL-024 | Phase 1 | Advanced Neuroendocrine Carcinoma | Oncology | Dec 2026 |
| NCT06049290 | LBL-034 | Phase 1 | Relapsed/Refractory Multiple Myeloma | Oncology | May 2027 |
| NCT07099430 | LBL-024 | Phase 1 | Advanced Melanoma | Oncology | Oct 2027 |
| NCT07323173 | LBL-047 | Phase 1 | Systemic Lupus Erythematosus | Immunology | Dec 2027 |
| NCT07042802 | LBL-024 | Phase 1 | Ovarian Cancer | Oncology | Dec 2027 |
| NCT07111546 | LBL-024 | Phase 2 | Advanced Solid Tumour | Oncology | Dec 2027 |
| NCT07281976 | LBL-024 | Phase 1 | Triple Negative Breast Cancer | Oncology | Dec 2027 |
| NCT07390383 | LBL-024 | Phase 2 | Advanced Solid Tumour | Oncology | May 2028 |
| NCT07331155 | LBL-024 | Phase 2 | Advanced Solid Tumour | Oncology | Dec 2028 |
| NCT07791758 | LBL-024 | Phase 1 | Metastatic Colorectal Carcinoma | Oncology | Sep 2030 |
No annotated target.
–
Jacobio Pharmaceuticals HighField Biopharmaceuticals HC Biopharma Nanjing IASO Biotechnology Molecure
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.